United Therapeutics Corporation $UTHR Shares Purchased by Brandes Investment Partners LP

Brandes Investment Partners LP increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 34.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 4,044 shares of the biotechnology company’s stock after acquiring an additional 1,027 shares during the period. Brandes Investment Partners LP’s holdings in United Therapeutics were worth $1,970,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 625,059 shares of company stock worth $352,648,188. 8.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Price Performance

Shares of UTHR opened at $544.10 on Thursday. The company has a market cap of $23.10 billion, a P/E ratio of 20.08, a PEG ratio of 1.80 and a beta of 0.57. The stock has a fifty day moving average price of $568.19 and a 200 day moving average price of $520.67. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.63 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.